FDA marks deadline for blockbuster Bydureon decision; Ironwood expenses grow in Q2

@FierceBiotech: Detector lets researchers see biomarkers with their naked eyes. News | Follow @FierceBiotech

@JohnCFierce: Highlights of the PwC VC report: Biotech deals and dollars are down year over year. Funding on early rounds grow. Report | Follow @JohnCFierce

@MaureenFierce: Paladin makes hostile bid for Afexa. Story | Follow @MaureenFierce

> The FDA has marked January 28, 2012 as its deadline for deciding--once again--whether or not Bydureon should be approved to treat diabetes. Amylin, Eli Lilly and Alkermes have been jockeying for an approval of the new treatment--a once-weekly successor to the blockbuster Byetta--for some time. Most recently the FDA demanded more safety data related to the drug's impact on the heart and in July the developers delivered a fresh set of data finding no link between the drug and potentially harmful changes in heart rhythm. Story

> Ironwood Pharmaceuticals, which recently filed linaclotide for approval, reported that its expenses grew in the second quarter. Ironwood last $18.8 million in Q2. Story

> San Francisco-based CytomX Therapeutics has named Sean McCarthy as its new CEO. Release

> Bohai Pharmaceuticals Group has acquired China's Yantai Tianzheng Pharmaceutical, which makes traditional Chinese remedies. Release

Pharma News

@FiercePharma: Vioxx lawyers are still playing tug-of-war on legal fees. Why? Because it works. Item | Follow @FiercePharma

> Breakthrough meds deliver the goods for BMS, Vertex. More

> New HIV med stands to boost J&J, Gilead by $500M. Story

> Vioxx securities-fraud case moves ahead. News

> Analysts love Teva, up or down. Details

> NEJM: Xarelto at least equal to warfarin. Report

Manufacturing News

> Vintage pharmacist bottles revered in NJ. More

> Cannines ID Pfizer fakes, discern brands. Details

> Greeley at CIS: alignments that speed time into market, aid compliance. News

> GSK leads pharma charge to middle east. Story

> Pfizer piggybacks PAT to real-time release. Article

Vaccine News

> Celldex stock hit had, but cancer vaccine shows promise. Story

> TB remedy could further the cancer fight. More

> Aeras kicks off TB trial in HIV patients. Report

> FBI raids San Diego's NexBio. Details

> University gets $4.8M grant for new rabies treatment. Story

And Finally... A team of scientists in the UK have identified 30 new genetic risk factors for multiple sclerosis, more than doubling the number of known genetic clues to the disease. Story

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.